Expression, prognostic value and potential immunotherapeutic target of COL1A1 in colon cancer

被引：1

作者：

Zeng, Xiang ^{[1
]}

Chen, Guoxue ^{[1
]}

Guo, Dunwei ^{[1
]}

Chen, Yong ^{[1
]}

Hu, Xinpeng ^{[1
]}

机构：

[1] Gen Hosp Yangtze River Shipping, Dept Gen Surg, Wuhan 430010, Hubei, Peoples R China

来源：

CELLULAR AND MOLECULAR BIOLOGY | 2023年 / 69卷 / 15期

关键词：

COL1A1; colon cancer prognosis; immunotherapy; TCGA; infiltration; TUMOR-ASSOCIATED MACROPHAGES; CHEMOTHERAPY; SIGNATURE; SURVIVAL; BLOCKADE; CELLS;

D O I：

10.14715/cmb/2023.69.15.21

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

This study aimed to investigate the link between COL1A1 production and colorectal carcinoma and assess the value of prognosis and immunotherapy. For this purpose, the transcriptional level of COL1A1 was analyzed. The clinicopathological information and gene expression profile were analyzed to reveal the link between COL1A1 and clinicopathological characteristics. For bioinformatics examination, GSEA and GSVA were utilized. Correlation analysis was implemented to study the causal relationship between COL1A1 and immune checkpoint molecules and inflammation immune cell infiltration. Results showed that in colorectal cancer, COL1A1 was highly expressed and linked with a few clinicopathological characteristics, inflammation and immunological response, tumor immune cell infiltration, and immune checkpoint markers. COL1A1 might likely indicate a bad prognosis and serve as a target of immunotherapy for colon cancer.

引用

页码：120 / 125

页数：6

共 27 条

[1] The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma
Almquist, Daniel R.
Ahn, Daniel H.
Bekaii-Saab, Tanios S.
[J]. BIODRUGS, 2020, 34 (03) : 349 - 362
[2] Expression of Genes Involved in Cellular Adhesion and Extracellular Matrix Remodeling Correlates with Poor Survival of Patients with Renal Cancer
Boguslawska, Joanna
Kedzierska, Hanna
Poplawski, Piotr
Rybicka, Beata
Tanski, Zbigniew
Piekielko-Witkowska, Agnieszka
[J]. JOURNAL OF UROLOGY, 2016, 195 (06) : 1892 - 1902
[3] 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
Cardoso, F.
van't Veer, L. J.
Bogaerts, J.
Slaets, L.
Viale, G.
Delaloge, S.
Pierga, J. -Y.
Brain, E.
Causeret, S.
DeLorenzi, M.
Glas, A. M.
Golfinopoulos, V.
Goulioti, T.
Knox, S.
Matos, E.
Meulemans, B.
Neijenhuis, P. A.
Nitz, U.
Passalacqua, R.
Ravdin, P.
Rubio, I. T.
Saghatchian, M.
Smilde, T. J.
Sotiriou, C.
Stork, L.
Straehle, C.
Thomas, G.
Thompson, A. M.
van der Hoeven, J. M.
Vuylsteke, P.
Bernards, R.
Tryfonidis, K.
Rutgers, E.
Piccart, M.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (08) : 717 - 729
[4] Tumor infiltrating immune cells in gliomas and meningiomas
Domingues, Patricia
Gonzalez-Tablas, Maria
Otero, Alvaro
Pascual, Daniel
Miranda, David
Ruiz, Laura
Sousa, Pablo
Ciudad, Juana
Maria Goncalves, Jesus
Lopes, Maria Celeste
Orfao, Alberto
Dolores Tabernero, Maria
[J]. BRAIN BEHAVIOR AND IMMUNITY, 2016, 53 : 1 - 15
[5] Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Herbst, Roy S.
Baas, Paul
Kim, Dong-Wan
Felip, Enriqueta
Perez-Gracia, Jose L.
Han, Ji-Youn
Molina, Julian
Kim, Joo-Hang
Arvis, Catherine Dubos
Ahn, Myung-Ju
Majem, Margarita
Fidler, Mary J.
de Castro, Gilberto, Jr.
Garrido, Marcelo
Lubiniecki, Gregory M.
Shentu, Yue
Im, Ellie
Dolled-Filhart, Marisa
Garon, Edward B.
[J]. LANCET, 2016, 387 (10027) : 1540 - 1550
[6] Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
Hodi, Frank Stephen
Chiarion-Sileni, Vanna
Gonzalez, Rene
Grob, Jean-Jacques
Rutkowski, Piotr
Cowey, Charles Lance
Lao, Christopher D.
Schadendorf, Dirk
Wagstaff, John
Dummer, Reinhard
Ferrucci, Pier Francesco
Smylie, Michael
Hill, Andrew
Hogg, David
Marquez-Rodas, Ivan
Jiang, Joel
Rizzo, Jasmine
Larkin, James
Wolchok, Jedd D.
[J]. LANCET ONCOLOGY, 2018, 19 (11) : 1480 - 1492
[7] Apoptosis of tumor infiltrating effector TIM-3+CD8+T cells in colon cancer
Kang, Chiao-Wen
Dutta, Avijit
Chang, Li-Yuan
Mahalingam, Jayashri
Lin, Yung-Chang
Chiang, Jy-Ming
Hsu, Chen-Yu
Huang, Ching-Tai
Su, Wan-Ting
Chu, Yu-Yi
Lin, Chun-Yen
[J]. SCIENTIFIC REPORTS, 2015, 5
[8] Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
Koyama, Shohei
Akbay, Esra A.
Li, Yvonne Y.
Herter-Sprie, Grit S.
Buczkowski, Kevin A.
Richards, William G.
Gandhi, Leena
Redig, Amanda J.
Rodig, Scott J.
Asahina, Hajime
Jones, Robert E.
Kulkarni, Meghana M.
Kuraguchi, Mari
Palakurthi, Sangeetha
Fecci, Peter E.
Johnson, Bruce E.
Janne, Pasi A.
Engelman, Jeffrey A.
Gangadharan, Sidharta P.
Costa, Daniel B.
Freeman, Gordon J.
Bueno, Raphael
Hodi, F. Stephen
Dranoff, Glenn
Wong, Kwok-Kin
Hammerman, Peter S.
[J]. NATURE COMMUNICATIONS, 2016, 7
[9] PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T.
Uram, J. N.
Wang, H.
Bartlett, B. R.
Kemberling, H.
Eyring, A. D.
Skora, A. D.
Luber, B. S.
Azad, N. S.
Laheru, D.
Biedrzycki, B.
Donehower, R. C.
Zaheer, A.
Fisher, G. A.
Crocenzi, T. S.
Lee, J. J.
Duffy, S. M.
Goldberg, R. M.
de la Chapelle, A.
Koshiji, M.
Bhaijee, F.
Huebner, T.
Hruban, R. H.
Wood, L. D.
Cuka, N.
Pardoll, D. M.
Papadopoulos, N.
Kinzler, K. W.
Zhou, S.
Cornish, T. C.
Taube, J. M.
Anders, R. A.
Eshleman, J. R.
Vogelstein, B.
Diaz, L. A., Jr.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (26) : 2509 - 2520
[10] Identification of COL1A1 and COL1A2 as candidate prognostic factors in gastric cancer
Li, Jun
Ding, Yuemin
Li, Aiqing
[J]. WORLD JOURNAL OF SURGICAL ONCOLOGY, 2016, 14

← 1 2 3 →